SRRK — Scholar Rock Holding Corporation

Scholar Rock (SRRK) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Operating Expenses: Reported at $102 million, including $80 million in non-cash stock-based compensation. Excluding this, operating expenses were $84 million.
• Cash Position: Ended the quarter with $480 million in cash, cash equivalents, and marketable securities, bolstered by a $100 million drawdown from a debt facility and $98 million from an ATM program.
• Future Financing: Plans to draw an additional $150 million from the debt facility upon FDA approval of apitegromab and to monetize a priority review voucher to enhance the balance sheet.

2. Strategic Updates and Business Highlights:

• FDA Submission: The FDA accepted the Biologics License Application (BLA) for apitegromab for spinal muscular atrophy (SMA) with a PDUFA action date set for September 30, 2026. The BLA includes two fill-finish facilities, allowing for independent paths to approval.
• Manufacturing Progress: The FDA completed an unannounced reinspection of the Catalent Indiana facility, with a classification decision expected within 90 days. A second fill-finish facility is on track to provide commercial supply by early Q3 2026.
• Commercial Readiness: The U.S. commercial team is prepared for an immediate launch upon approval, with ongoing disease awareness initiatives and engagement with approximately 140 SMA treatment centers and 2,600 prescribing physicians.
• European Market: The Marketing Authorization Application (MAA) for apitegromab in Europe is progressing well, with a Committee for Medicinal Products for Human Use (CHMP) opinion expected mid-year.

3. Forward Guidance and Outlook:

• Launch Plans: Scholar Rock is poised for a transformative year with expectations to launch apitegromab in both the U.S. and Europe in the second half of 2026. The company anticipates serving up to 35,000 patients globally who have received SMN-targeted therapies.
• Pipeline Development: Continued advancement in the anti-myostatin pipeline, including the Phase II OPAL study for infants and toddlers with SMA and the upcoming FORGE trial for facioscapulohumeral muscular dystrophy (FSHD).

4. Bad News, Challenges, or Points of Concern:

• Regulatory Risks: The reliance on the Catalent facility poses a risk if the FDA classification is unfavorable, although the company has mitigated this by having a second facility.
• Market Competition: The recent approval of Itvisma for older SMA patients raises questions about the competitive landscape and potential treatment combinations, which may affect market dynamics.
• Uncertainty in Labeling: There are ongoing discussions regarding the breadth of the label for apitegromab, particularly concerning its applicability across different SMA types and age groups.

5. Notable Q&A Insights:

• Regulatory Confidence: Management expressed confidence in the FDA's collaborative approach and the likelihood of successful classification for the Catalent facility, while also emphasizing the importance of having two facilities for redundancy.
• Commercial Strategy: The company is focused on positioning apitegromab as complementary to existing SMN-targeted therapies, rather than competing with them, and is preparing for a dual launch in the U.S. and Germany.
• Investigator Interest: Following Roche's discontinuation of Emugrobart for FSHD, there has been increased interest from investigators in apitegromab, highlighting the potential for its use in this indication.

Overall, Scholar Rock is strategically positioned for a pivotal year with significant advancements in regulatory submissions and commercial readiness, despite facing regulatory and competitive challenges.